ENHERTU Shows Promising Results in Breast Cancer Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Source: Newsfilter
- Clinical Trial Results: The DESTINY-Breast05 phase 3 trial demonstrated that ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1, indicating its potential as a new standard of care in early breast cancer treatment.
- Regulatory Progress: The European Medicines Agency has validated the marketing authorization application for ENHERTU, marking the commencement of the scientific review process, which is expected to expedite its availability for eligible patients in need of better treatment options.
- Patient Recruitment: The DESTINY-Breast05 trial enrolled 1,635 patients across Asia, Europe, and North America, showcasing the drug's broad applicability and potential market reach on a global scale.
- Future Development Directions: Additional regulatory submissions for ENHERTU are underway, including its combination with pertuzumab for the treatment of unresectable or metastatic HER2 positive breast cancer, highlighting its potential across multiple indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
